Statistics

Total Visits

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone70

Select a period of time:

Number of views in the range

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone38

Views

Views
November 20243
December 20249
January 20254
February 20255
March 202511
April 20255
May 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States22
Singapore6
United Arab Emirates2
Spain2
Finland2
United Kingdom2
Italy2
 

Top cities views

Views
London2
Helsinki2
Council Bluffs1
Dallas1
Los Angeles1